BioInvent International AB Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest, by Erik Esveld, was filed 23 Feb 2024.
BioInvent International AB: what insiders have been doing
Every trade that managers of BioInvent International AB disclose to Finansinspektionen is tracked on this page. No insider at BioInvent International AB has published a filing in the past twelve months. The most recent one dates from 23 February 2024.
Looking back to 2018, when coverage begins, insiders filed 75 purchases and 6 sales.
For comparison within the same market, see the insider buying recorded at Dynavox Group AB and Rusta AB (publ). This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.
Since the insiders bought
- -33.0%Entry 48.66 · Close at T+365 32.60
- +20.4%Entry 36.04 · Close at T+365 43.40
- +6.8%Entry 37.56 · Close at T+365 40.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
- 5,200 shares@ SEK 16.2628.0% of flowAktieISIN SE0015244520FI:csv-4beef52ab5071be660d1Canonical exit: 23 May 2024 (T+90)
- 4,000 shares@ SEK 17.7423.4% of flowAktieISIN SE0015244520FI:csv-048c30a7f4cc692352abCanonical exit: 8 Apr 2024 (T+90)
- 8,800 shares@ SEK 17.775748.7% of flowAktieISIN SE0015244520FI:csv-09df7ebc44488b2043acCanonical exit: 30 Nov 2023 (T+90)
- 10,000 shares@ SEK 16.32258.4% of flowAktieISIN SE0015244520FI:csv-d4e427b8c683753f3bd0Canonical exit: 28 Nov 2023 (T+90)
- 3,680 shares@ SEK 16.803.2% of flowAktieISIN SE0015244520FI:csv-d98b07b1399cf5d8d6c8Canonical exit: 28 Nov 2023 (T+90)
- 4,133 shares@ SEK 16.403.5% of flowAktieISIN SE0015244520FI:csv-99870f396dd352f86c9dCanonical exit: 28 Nov 2023 (T+90)
- 10,000 shares@ SEK 16.948.7% of flowAktieISIN SE0015244520FI:csv-8d9cdf6b43c6a27fc4b3Canonical exit: 28 Nov 2023 (T+90)
- 8,187 shares@ SEK 17.247.2% of flowAktieISIN SE0015244520FI:csv-852f6438af85a90a546fCanonical exit: 28 Nov 2023 (T+90)
- 14,000 shares@ SEK 17.0018.8% of flowAktieISIN SE0015244520FI:csv-5665ad17ea9d02b78c6bCanonical exit: 11 Oct 2023 (T+90)
- 5,000 shares@ SEK 18.6329100.0% of flowAktieISIN SE0015244520FI:csv-937f881d254b5c2a5b32Canonical exit: 28 Sept 2023 (T+90)
- 1,250 shares@ SEK 35.5010.8% of flowAktieISIN SE0000789711FI:csv-2258e1717e4a211c99aeCanonical exit: 12 Mar 2023 (T+90)
- 10,000 shares@ SEK 35.2519.2% of flowAktieISIN SE0015244520FI:csv-9c2c6568ada63b525948Canonical exit: 14 Feb 2023 (T+90)
- 951,200 shares0TeckningsoptionFI:csv-d2fe45a90a50e9916ec1
- 500 shares@ SEK 33.602.6% of flowAktieISIN SE0015244520FI:csv-cd49cd9051edd04578aaCanonical exit: 7 Jun 2022 (T+90)
- 530 shares@ SEK 32.442.6% of flowAktieISIN SE0015244520FI:csv-ca21bbbf8bb42ffa078cCanonical exit: 7 Jun 2022 (T+90)
- 3,262 shares@ SEK 33.6616.7% of flowAktieISIN SE0015244520FI:csv-e8769306af95a6c2f029Canonical exit: 7 Jun 2022 (T+90)
- 200 shares@ SEK 33.701.0% of flowAktieISIN SE0015244520FI:csv-7f07acec171f9af38336Canonical exit: 7 Jun 2022 (T+90)
- 611 shares@ SEK 33.883.2% of flowAktieISIN SE0015244520FI:csv-d73d5dbe2e6745b17418Canonical exit: 7 Jun 2022 (T+90)
- 750 shares@ SEK 33.903.9% of flowAktieISIN SE0015244520FI:csv-93cf6b748202a47d3239Canonical exit: 7 Jun 2022 (T+90)
- 800 shares@ SEK 34.004.1% of flowAktieISIN SE0015244520FI:csv-8b4ea30f288982bd913aCanonical exit: 7 Jun 2022 (T+90)
- 18 shares@ SEK 34.020.1% of flowAktieISIN SE0015244520FI:csv-01e8de8e60c32668af4cCanonical exit: 7 Jun 2022 (T+90)
- 329 shares@ SEK 34.061.7% of flowAktieISIN SE0015244520FI:csv-e9219e700b66467198b5Canonical exit: 7 Jun 2022 (T+90)
- 400 shares@ SEK 34.282.1% of flowAktieISIN SE0015244520FI:csv-90db62a27f49db2418abCanonical exit: 7 Jun 2022 (T+90)
- 295,492 shares0OptionFI:csv-6edaba7c6f41c7ad3379
- 2,527 shares@ SEK 39.905.9% of flowAktieISIN SE0015244520FI:csv-d1284b5b467aac77cab6Canonical exit: 20 Apr 2022 (T+90)
25 of 121 declarations
About BioInvent International AB
BioInvent International AB is a Swedish biopharmaceutical company focused on developing innovative cancer treatments. It is listed on the XSTO market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations